New Analysis reinforces Vascepa/Vaskepa (icosapent ethyl) reduced cardiovascular events in high-risk patients – Amarin
Amarin Corporation highlighted a new post hoc analysis of aspirin use in REDUCE-IT® reinforcing that icosapent ethyl significantly reduced cardiovascular (CV) events in high-risk patients. These findings highlight the… read more.
